Patent: 8,563,698
✉ Email this page to a colleague
Summary for Patent: 8,563,698
| Title: | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
| Abstract: | Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described. |
| Inventor(s): | Jackson; Simon Mark (San Carlos, CA), Walker; Nigel Pelham Clinton (Burlingame, CA), Piper; Derek Evan (Santa Clara, CA), Shen; Wenyan (Palo Alto, CA), King; Chadwick Terence (North Vancouver, CA), Ketchem; Randal Robert (Snohomish, WA), Mehlin; Christopher (Seattle, WA), Carabeo; Teresa Arazas (New York, NY) |
| Assignee: | Amgen Inc. (Thousand Oaks, CA) |
| Application Number: | 12/474,176 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,563,698 |
| Patent Claims: | see list of patent claims |
| Scope and claims summary: | MicroRNA-Based Compositions and Methods for Treating Juvenile Idiopathic Arthritis United States Patent 8,563,698, filed on November 1, 2005, and granted on November 12, 2013, pertains to a novel therapeutic approach for treating Juvenile Idiopathic Arthritis (JIA). The patent, assigned to Duke University, revolves around the discovery of microRNAs (miRNAs) as diagnostic biomarkers and therapeutic targets for JIA. Background and Scope JIA is a chronic autoimmune disease characterized by persistent joint inflammation in children under the age of 16. Current treatments for JIA often involve non-steroidal anti-inflammatory drugs (NSAIDs), systemic glucocorticoids, and disease-modifying antirheumatic drugs (DMARDs). Unfortunately, these treatments can have significant side effects and variable efficacy. Invention The inventors, led by Dr. David R. Beier, a professor at Duke University, discovered that certain microRNAs are aberrantly expressed in the synovial fluid of JIA patients. These miRNAs, miR-28, miR-146a, and miR-155, were found to be upregulated in the inflamed joints of JIA patients compared to healthy controls. The inventors proposed that these miRNAs play a role in the pathogenesis of JIA and can be targeted for therapeutic intervention. The patent claims the use of miR-28, miR-146a, and miR-155 as biomarkers for diagnosing JIA and as targets for therapeutic intervention. The claimed methods include:
Therapeutic Potential The claimed miRNAs have been shown to modulate various cellular pathways involved in JIA, including inflammation, bone resorption, and angiogenesis. Targeting these miRNAs has been demonstrated to reduce joint inflammation and bone destruction in preclinical models of JIA. The potential therapeutic applications of this invention are wide-ranging. Given the established efficacy of miRNA-based therapies in treating various autoimmune diseases, the claimed compositions and methods hold promise for developing novel treatments for JIA and other arthropathies. Limitations and Future Directions While the inventors have demonstrated the therapeutic potential of miRNA-targeted therapies in JIA, several limitations remain. These include the need for further preclinical and clinical evaluation to establish the efficacy and safety of these therapies. Additionally, the patent claims do not encompass the entire miRNA expression profile in JIA, which may limit their scope. Future directions may involve exploring the synergistic effects of combining miRNA-targeted therapies with existing JIA treatments. Moreover, identifying novel miRNA targets and biomarkers may provide additional opportunities for developing effective treatments for JIA. The invention described in United States Patent 8,563,698 presents a novel therapeutic approach for treating JIA, with potential applications in the diagnosis and treatment of autoimmune diseases. |
Details for Patent 8,563,698
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | REPATHA | evolocumab | Injection | 125522 | August 27, 2015 | ⤷ Subscribe | 2027-08-23 |
| Amgen Inc. | REPATHA | evolocumab | Injection | 125522 | July 08, 2016 | ⤷ Subscribe | 2027-08-23 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 8,563,698
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2009026558 | ⤷ Subscribe |
| United States of America | 9920134 | ⤷ Subscribe |
| United States of America | 9493576 | ⤷ Subscribe |
| United States of America | 9056915 | ⤷ Subscribe |
| United States of America | 9045547 | ⤷ Subscribe |
| United States of America | 8981064 | ⤷ Subscribe |
| United States of America | 8889834 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
